KUALA LUMPUR, March 18 (Bernama) -- AstraZeneca has made its rare disease treatment Soliris available in Malaysia, marking a significant advancement in treatment options for patients with rare ...
C5b initiates the membrane attack pathway, which results in the membrane attack complex (MAC), consisting of C5b, C6, C7, C8, and polymeric C9. MAC is the cytolytic endproduct of the complement ...
(MENAFN- GlobeNewsWire - Nasdaq) The complement inhibitors market is gaining momentum due to the rising recognition of the complement system's role in driving rare and chronic diseases, such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results